<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Torres, Roarelis</style></author><author><style face="normal" font="default" size="100%">Wolfgang, Curt</style></author><author><style face="normal" font="default" size="100%">Weiden, Peter J</style></author><author><style face="normal" font="default" size="100%">Hamilton, Jennifer</style></author><author><style face="normal" font="default" size="100%">Stahl, Stephan M</style></author><author><style face="normal" font="default" size="100%">Lauriello, John</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Iloperidone for the Treatment of Schizophrenia—Selected Posters</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-15</style></pages><abstract><style  face="normal" font="default" size="100%">Over 50% of schizophrenia patients drop out of controlled trials within 6 months due to lack of efficacy or in some cases tolerability issues [Liu-Siefert et al. BMC Med 2005; Lieberman JA et al. N Engl J Med 2005], particularly extrapyramidal symptoms (EPS), akathisia, weight gain, metabolic effects, sedation, and anticholinergic effects. EPS and akathisia effects carry an increased risk of suicide [Dong JY et al. J Affect Disord 2005] and poor adherence, while metabolic effects can increase the risk for diabetes and cardiovascular disease. Iloperidone, a mixed D2/5-HT2 antagonist that is under US Federal Drug Administration (FDA) review, may provide a lower EPS/akathisia liability.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>